Monoclonal antibodies and multifunctional cytochrome P450: Drug metabolism as paradigm

Journal of Clinical Pharmacology

Volumn 46, Issue 3, 2006, Pages 353-372

  Gelboin, Harry V ^a   Krausz, Kristopher ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytochrome P450; Drug discovery; Drug metabolism; Monoclonal antibodies

Indexed keywords

ACETALDEHYDE; ANTICOAGULANT AGENT; BUFURALOL; COUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450; DEXTROMETHORPHAN; DIAZEPAM; DICLOFENAC; ENDOCRINE DISRUPTOR; ETHOXYCOUMARIN; IFOSFAMIDE; KETOCONAZOLE; MEPHENYTOIN; METHOXYCHLOR; MONOCLONAL ANTIBODY; NORDAZEPAM; NORFLUOXETINE; ORPHENADRINE; PACLITAXEL; PARACETAMOL; PESTICIDE; PHENACETIN; PHENANTHRENE; QUINIDINE; REPAGLINIDE; TEMAZEPAM; TOLBUTAMIDE; UNINDEXED DRUG; XENOBIOTIC AGENT;

AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; CATALYSIS; DEMETHYLATION; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HYDROXYLATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER MICROSOME; MOLECULAR INTERACTION; NEPHROTOXICITY; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REVIEW;

ALLELES; ANTIBODIES; ANTIBODIES, MONOCLONAL; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PROTEIN ISOFORMS;

EID: 32944455130     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005285200     Document Type: Review

References (52)

1. McCann J, Choi E, Yamaski E, Ames BN. Detection of carcinogens mutagens in the salmonella/microsome test: as chemicals. PNAS. 1975 ; 72: 5135-5139.
2. Gelboin HV. Amicrosome-dependent binding of benzo[a]pyrene to DNA1. Cancer Res. 1969 ; 29: 1272-1276.
3. Bartsch H. Hunting for electrophiles that harm human DNA: Frits Sobels award lecture. Mutagenesis. 2002 ; 17: 281-287.
4. Yang SK, McCourtDW, Leutz JC, Gelboin HV. Benzo(a)pyrene diolepoxides: mechanism of enzymatic formation and optically active intermediates. Science. 1977 ; 196: 1199-1201.
5. Furlong BB, Weaver RP, Goldstein JA. Covalent binding to DNA and mutagenicity of 2,4-diaminotoluene metabolism produced by isolated hepatocytes and 9000 g supernatant from Fischer 344 rats. Carcinogenesis. 1987 ; 8: 247-251.
6. Gelboin HV. Monoclonal antibodies and cytochrome P450. Pharmacol Rev. 1993 ; 45: 413-453.
7. Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drugdiscovery. Trends Pharmacol Sci. 1999 ; 20: 432-438.
8. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 ; 256: 495-497.
9. Burnet M. The Clonal Selection Theory of Acquired Immunity. Nashville, Tenn: Vanderbilt University Press ; 1959.
10. Park SS, Person AV, Coon MJ, Gelboin HV. Monoclonal antibodies to rabbit liver cytochrome P-450 LM2. FEBS Lett. 1980 ; 116: 231-235.
11. Park SS, Fujino T, West D, Guengerich FP, Gelboin HV. Monoclonal antibodies inhibiting enzyme activity of cytochrome P450 from 3-methycholanthracene-treated rats. Cancer Res. 1982 ; 42: 1798-1808.
12. Battula N, Sagara J, Gelboin HV. Expression of P1-450 and P3-450 DNAcoding sequences as enzymatically active cytochromes P-450 in mammalian cells. PNAS USA. 1987 ; 84: 4073-4077.
13. Gonzalez FJ, Kimura S, Tamura S, Gelboin HV. Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol. 1991 ; 206: 93-99.
14. Gelboin HV, Shou M, Goldfarb I, Yang TJ, Krausz KW. Monoclonal antibodies to cytochromes P450. In: Phillips IR, Shephard EA, eds. Methods in Molecular Biology: Cytochrome P450 Protocols. Totowa, NJ: Humana ; 1998: 227-237.
15. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 ; 265: 401-407.
16. Fujino T, Park SS, West D, Gelboin HV. Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proc Natl Acad Sci USA. 1982 ; 79: 3682-3686.
17. Fujino T, Gottlieb K, Manchester DK, et al. Monoclonal antibody phenotyping of inter-individual differences in cytochrome P-450 dependent reactions of single and twin human placenta. Cancer Res. 1984 ; 44: 3916-3923.
18. Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 ; 8: 391-401.
19. Sai Y, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics. 1999 ; 9: 229-237.
20. Yang TJ, Krausz KW, Shou M, et al. Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 ; 55: 1633-1640.
21. Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelboin HV. Eight inhibitory monoclonal antibodies define the role of individual P450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism. DMD. 1999 ; 27: 102-109.
22. Krausz KW, Goldfarb I, Buters JTM, Yang TJ, Gonzalez FJ, Gelboin HV. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9 and 2C19. Drug MetabDispos. 2001 ; 29: 1410-1423.
23. Krausz KW, Yang TJ, Shou M, Gonzalez FJ, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem Pharmacol. 1997 ; 54: 15-17.
24. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, Yang TJ. A monoclonal antibody inhibitory to human cytochrome P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics. 1997 ; 7: 469-477.
25. Gelboin HV, Goldfarb I, Krausz KW, et al. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 2E1. Res Toxicol. 1996 ; 9: 1023-1030.
26. Xiao YF, Ke Q, Seubert JM, et al. Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol. 2004 ; 66: 1607-1616.
27. Gelboin HV, Krausz KW, Goldfarb I, et al. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol. 1995 ; 50: 1841-1850.
28. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in themetabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998 ; 8: 391-401.
29. Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001 ; 41: 535-567.
30. McFayden MCE, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999 ; 47: 1457-1464.
31. Forkert PG, Vessey ML, Park SS, Gelboin HV, Cole SPC. Cytochromes P-450 in murine lung: an immunohistochemical study with monoclonal antibodies. Drug Metab Dispos. 1989 ; 17: 551-555.
32. Forkert PG, Massey TE, Jones AB, Park SS, Gelboin HV, Anderson LM. Distribution of cytochrome CYP2E1 inmurine liver after ethanol and acetone administration. Carcinogenesis. 1991 ; 12: 2259-2268.
33. Mei Q, Yang C, Lin Y, Rushmore TH, Shou M. Inhibition kinetics of monoclonal antibodies against cytochromes P450. Drug Metab Dispos. 2002 ; 30: 701-708.
34. Turner KJ, MacPherson S, Millar MR, et al. Development and validation of a new monoclonal antibody to mammalian aromatase. J Endocrinol. 2002 ; 172: 21-30.
35. Krausz KW, Goldfarb I, Yang TJ, Gonzalez FJ, Gelboin HV. An inhibitory monoclonal antibody to human cytochrome P450 that specifically binds and inhibits P450 2C9II, an allelic variant of P450 2C9 having a single amino acid change Arg144Cys. Xenobiotica. 2000 ; 30: 619-625.
36. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. Identification of cytochrome P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 ; 60: 173-182.
37. Hu Y, Krausz K, Gelboin HV, Kupfer D. CYP2C subfamily, primarily CYP2C9, catalyses the enantioselective demethylation of the endocrine disrupter pesticide methoxychlor in human liver microsomes: use of inhibitory monoclonal antibodies in P450 identification. Xenobiotica. 2004 ; 34: 117-117.
38. Aleska K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. Cytochrome P4503Aand 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol. 2005 ; 20: 872-885.
39. Davit B, Reynolds K, Yuan R, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. Drug Development. 1999 ; 39: 899-910.
40. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 ; 10: 187-216.
41. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002 ; 30: 1311-1319.
42. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphichydroxylation of debrisoquine inman. Lancet. 1977 ; 2: 584-586.
43. Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA. Identification of the human cytochrome P450 responsible for in vitro formation of R- and S-norfluoxetine. Pharmacol Exp Ther. 2001 ; 297: 1044-1050.
44. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principle enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003 ; 56: 305-314.
45. Hutchinson MR, Menalaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidativemetabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 ; 57: 287-297.
46. Le Gal A, Dreano Y, Lucas D, Berthou F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and Nnitrosobenzylmethylamine. Toxicol Lett. 2003 ; 144: 77-91.
47. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol. 2001 ; 51: 281-285.
48. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17aplhaethinylestradiol. Drug Metab Dispos. 2004 ; 32: 1209-1212.
49. Granvil C, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. Pharmacol Exp Ther. 2002 ; 301: 1025-1032.
50. Sai Y, Dai R, Yang TJ, et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochrome P450. Xenobiotica. 2000 ; 30: 327-343.
51. Soars MG, Gelboin HV, Krausz KW, Riley RJ. Acomparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol. 2003 ; 55: 75-81.
52. Lu AYH, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos. 2003 ; 31: 345-350.